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1. Introduction
Between September 2003 and December 2009, the
ENRY (European Network on Radioembolisation with
Yttrium-90 resin microspheres) group collated data on
325 consecutive patients with a conﬁrmed diagnosis of
hepatocellular carcinoma (HCC) who received selective
internal radiation therapy (SIRT), also known as radio-
embolisation, with yttrium-90 (90Y) resin microspheres
(SIR-Spheres®) at eight European centres. 1 Multiple
analyses were conducted according to disease stage,
prior treatment and key prognostic markers such as
liver function (as measured by individual variables such
as bilirubin levels or by composite variables such as the
Child–Pugh score) and tumour burden (as measured by
nodularity, portal vein thrombosis [PVT], extrahepatic
disease [EHD] or performance status). These analyses
have helped provide some important insights into
questions of the safety and efﬁcacy of this procedure
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and enabled more meaningful comparison with other
treatments in patients with the same stage of disease. 1
The ENRY study population had primarily good liver
function (Child–Pugh class A; 82.5%), underlying cir-
rhosis (78.5%) and Eastern Cooperative Oncology Group
(ECOG) performance status (ECOG 1; 45.7%). Many had
multinodular disease (75.9%), invading both lobes (53.1%)
including some with high alpha-fetoprotein (>400ng/mL;
34.9%), PVT (23.3%) and EHD (9.2%). Most patients (93.2%)
received SIRT as a single procedure (median activity
administered 1.6GBq) and were followed-up for a median
of 10.0 months.
2. Safety and tolerability
ENRY provides a comprehensive analysis of the safety
and tolerability of SIRT in a cohort with a high incidence
of cirrhosis. 1 Patients were assessed for procedure-
related adverse events up to 7 days post-SIRT and
thereafter, for radiation-related adverse events up to
3 months. Overall, there was a low incidence of mainly
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Table 1 – Main procedure-related clinical adverse events by severity in HCC patients treated with
90Y resin microspheres 1
Adverse event CTCAE v3: No. (%)
All Grades Grade 1 Grade 2 Grade 3 Grade 4
Nausea and/or vomiting 104 (32.0%) 89 (27.4%) 14 (4.3%) 1 (0.3%) 0
Abdominal pain 88 (27.0%) 70 (21.5%) 13 (4.0%) 5 (1.5%) 0
Fever 40 (12.3%) 36 (11.1%) 4 (1.2%) 0 0
Fatigue 112 (34.5%) 100 (30.8%) 10 (3.1%) 2 (0.6%) 0
Procedure-related events (fatigue, nausea and vomiting, abdominal pain and fever) were evaluated from day 1 to day 7.
CTCAE v3: Common Terminology Criteria for Adverse Events version 3.0.
Table 2 – Main radiation-related laboratory adverse events by severity in HCC patients treated
with 90Y resin microspheres 1
Organ Variable All Grades
Pre-treatment Month 3
Grade 3
Pre-treatment Month 3
Liver Bilirubin 22.6% 48.6% * 0.0% 5.8% *
Albumin 38.0% 39.7% 0.0% 0.8%
INR 22.4% 31.4% 0.0% 1.8%
ALT 59.6% 57.4% 1.8% 3.3%
Creatinine 8.3% 11.6% 0.4% 1.4%
Platelets 44.4% 52.6% 2.2% 3.4%
GI tract GI ulcers 0 3.7% 0 1.8%
Lungs Pneumonitis 0 0 0 0
Radiation-related events were evaluated from day 8 to month 3.
CTCAE v3: Common Terminology Criteria for Adverse Events version 3.0
*p-value <0.001 by exact McNemar test comparing Grade 3−4 CTCAE at month 3 versus Grade 3−4 pre-SIRT.
mild, transient post-procedural adverse events (Table 1). 1
The incidence of radiation-related events was generally
unremarkable except for an increase in the proportion of
patients with raised bilirubin levels compared with the
pretreatment assessment (Table 2). 1
3. Survival
Median survival was 13.1 months (95% conﬁdence
interval [CI] 10.9–15.8) and varied signiﬁcantly by
Barcelona Clinic Liver Cancer (BCLC) stage (Fig. 1).
3.1. Is age a limitation for SIRT?
In patients stratiﬁed by age (<70yrs or 70yrs),
median survival (95%CI) was similar regardless of age:
12.8 months (10.8–17.9) vs 14.5 months (10.6–16.8),
respectively in each group (p=0.942). 1 SIRT was equally
well tolerated in both populations.
3.2. Is SIRT suitable for Child–Pugh B patients?
Reduced functional reserve and impaired regenerative
ability of the cirrhotic liver increase the risk of liver
failure, especially for patients who have had prior
extensive resection, or liver insult from toxins, acute
viral hepatitis or external irradiation. In the ENRY
analyses, patients receiving SIRT with Child–Pugh B had
a shorter median survival (95%CI) than patients with
Child–Pugh A: 10.0 months (6.1–13.8) vs. 14.9 months
(11.9–17.1); p = 0.006. Key factors, such as the presence of
ascites, were thought to contribute to the lower survival
with SIRT: median survival (95%CI) with and without
ascites: 6.1 months (4.4−8.6) vs. 14.1 months (11.8–17.9);
p< 0.001.
3.3. How does SIRT compare with transarterial
chemoembolisation (TACE) in intermediate-stage HCC?
Typical candidates for SIRT have either advanced- or
intermediate-stage HCC and are generally considered
poor candidates for TACE. By contrast, the main
randomised studies supporting the efﬁcacy and safety
of TACE are primarily in intermediate- and early-stage
disease including patients who cannot be treated with
radical therapies because of either age, tumour size and
location, cirrhosis or comorbidities. There are, however,
several series with TACE that include patients with
intermediate- and even advanced-stage disease. In a
recent case series evaluation analyzed by BCLC stage,
TACE (n=172) 2 was found to be broadly equivalent
to SIRT (n=325) 1 with median overall survivals of
17.4 months (95%CI 13.9–18.8) and 16.9 months (95%CI
12.8–22.8), respectively, in intermediate- (BCLC) stage ‘B’.
These ﬁndings are supported by a third large case series
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Fig. 1 – Survival of HCC patients treated with 90Y resin microspheres stratiﬁed by BCLC stage. Reproduced with permission
from Sangro B, Carpanese L, Cianni R et al., 1 on behalf of European Network on Radioembolization with yttrium-90 resin
microspheres (ENRY). Survival after 90Y resin microsphere radioembolization of hepatocellular carcinoma across BCLC stages:
A European evaluation. Hepatology 2011;54:868−78.
from the USA in BCLC stage ‘B’ HCC, which found
that patients receiving SIRT with 90Y-glass microspheres
(n=291) had a median overall survival of 17.2 months
(95%CI 13.5–29.6 months). 3
Importantly, data from ENRY show that survival
following SIRT appears particularly promising for the
subset of patients with intermediate-stage HCC who are
considered poor candidates for TACE (i.e. those with
bilobar and/or multiple [>5] tumors; median survival:
15.4–16.6 months) as well as for those who had failed
prior TACE or transarterial embolisation (TAE) (median
survival: 15.4 months). 1
3.4. How does SIRT compare to sorafenib in the advanced-
stage population?
More than half the candidates (56.3%) for SIRT from the
ENRY study had advanced- (BCLC) stage C HCC due to
the presence of either vascular invasion, EHD or altered
cancer-related performance status.
Median survival in this subset was 10.0 months (95%CI
7.7–10.9) and treatment was well-tolerated, although
fatigue (mostly mild grade 1 events) was more common
in patients with deteriorating ECOG performance sta-
tus. 4 Investigators found that SIRT was as effective and
equally well tolerated in patients with and without PVT
without any signiﬁcant reduction in overall survival or
increased risk of laboratory parameter adverse events. 4
It is notable that comparisons of the populations from
the ENRY and sorafenib studies include a very similar
population of patients with mixed intermediate- and
advanced-stage HCC, 5 although the studies of sorafenib
tended to include a higher percentage of patients with
EHD, particularly in the Asia-Paciﬁc trial 6. Even so, 58%
(189 of 325) of patients from the ENRY cohort matched
the inclusion criteria for the SHARP trial. Analyses of
these cohorts found a signiﬁcant overlap in terms of
overall survival between the two treatment modalities, 7
with a median overall survival with SIRT of 10.8 months
(95% CI: 8.8–12.8) in SHARP-equivalents and 10.2 months
(95% CI: 8.3–11.8) in a subset of these patients with
PVT or EHD. Studies are ongoing to evaluate the relative
safety and efﬁcacy of these two treatments either in
combination or as monotherapies.
4. Conclusion
SIRT appears to be a particularly promising treatment
in cohorts who may not otherwise be considered for
locoregional therapy, i.e. patients with intermediate-
stage HCC who are poor candidates for TACE (bilobar
and/or multiple tumours) and/or have failed prior
TACE/TAE, or patients with advanced-stage HCC, partic-
ularly those with PVT. Further prospective evaluations of
the clinical beneﬁt for SIRT in these patient populations
are warranted.
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